Literature DB >> 26820317

Canadian Association of General Surgeons position statement: recommendations for surgeons with blood-borne communicable diseases.

Sean Cleary1, Karen Doucette1, Christopher J Doig1, Carla Coffin1, David Grant1, Elijah Dixon1.   

Abstract

SUMMARY: The potential for transmission of hematogenously transmitted pathogens during exposure-prone procedures is a clinically important concern to both patients and surgeons. There is inconsistency among regulatory bodies in Canada regarding the management of infection risk among surgeons, particularly with regard to screening and the postexposure management of infected surgeons. The Canadian Association of General Surgeons commissioned a task force to review the evidence regarding the management of blood-borne pathogens and transmission risk during surgical procedures. The results of this review indicate a need for several jurisdictions to update their guidelines to reflect current evidence-based practices.

Entities:  

Mesh:

Year:  2016        PMID: 26820317      PMCID: PMC4814275          DOI: 10.1503/cjs.007615

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  4 in total

Review 1.  Proceedings of the Consensus Conference on Infected Health Care Worker Risk for transmission of bloodborne pathogens.

Authors: 
Journal:  Can Commun Dis Rep       Date:  1998-07

2.  Recommendations for preventing transmission of human immunodeficiency virus and hepatitis B virus to patients during exposure-prone invasive procedures.

Authors: 
Journal:  MMWR Recomm Rep       Date:  1991-07-12

3.  SHEA guideline for management of healthcare workers who are infected with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus.

Authors:  David K Henderson; Louise Dembry; Neil O Fishman; Christine Grady; Tammy Lundstrom; Tara N Palmore; Kent A Sepkowitz; David J Weber
Journal:  Infect Control Hosp Epidemiol       Date:  2010-03       Impact factor: 3.254

4.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.